Education
About Us
Working with TipRanks
Follow Us
OmniAb (OABI)
NASDAQ:OABI
OABI Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.22 - $4.96
Previous CloseN/A
Volume80.31K
Average Volume (3M)1.03M
Market Cap
$214.09M
Enterprise Value$299.55M
Total Cash (Recent Filing)$43.59M
Total Debt (Recent Filing)$22.48M
Price to Earnings (P/E)―
Beta1.13
Next Earnings
Aug 07, 2025EPS Estimate
-0.15Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.17
Shares Outstanding122,335,335
10 Day Avg. Volume1,304,853
30 Day Avg. Volume1,031,803
Financial Highlights & Ratios
PEG Ratio0.65
Price to Book (P/B)0.90
Price to Sales (P/S)0.00
P/FCF Ratio-14.80
Enterprise Value/Market Cap1.40
Enterprise Value/Revenue3.14
Enterprise Value/Gross Profit31.23
Enterprise Value/Ebitda-1.32
Forecast
1Y Price Target
$7.67Price Target Upside351.18% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
OmniAb News
PremiumCompany Announcements
OmniAb Elects Directors at Annual Shareholder Meeting
PremiumCompany Announcements
OmniAb’s Earnings Call: Growth Amid Challenges
PremiumCompany Announcements
OmniAb Reports Steady Growth in Q1 2025
Bulls Say, Bears Say
Bulls Say
Licensing AgreementsOmniAb signed three licensing partnerships in the quarter, including ones with Wyss Institute at Harvard, Italy-based Takis Biotech, and Orion, also private, based in Finland.
Product LaunchThe new product launch, xPloration instrument, is seen as upside to 2025 estimates and is differentiated on its speed, scale, and its significant ease of use in antibody screening workflows.
Program GrowthOmniAb continued to expand its partnered programs, reaching 95 active partners and 378 active programs by the end of 1Q25.
Bears Say
Financial OutlookQuestions about its $43M cash balance vs ~$38M FY25 cash burn remain, but management is confident the milestones in the post-discovery phase can get them to cash flow profitability.
Revenue ShortfallQ1 revenues of $4.2M were just below consensus $4.5M but largely driven by $2.0M in Milestone revenues.
Service Revenue DeclineMilestone revenues were slightly offset by a -30% year-over-year decrease in Service revenues following completion of certain small molecule ion channel programs.
Ownership Overview
32.14% Insiders
21.58% Mutual Funds
19.41% Other Institutional Investors
18.13% Public Companies and Individual Investors
OABI FAQ
What was OmniAb’s price range in the past 12 months?
OmniAb lowest stock price was $1.22 and its highest was $4.96 in the past 12 months.
What is OmniAb’s market cap?
OmniAb’s market cap is $214.09M.
When is OmniAb’s upcoming earnings report date?
OmniAb’s upcoming earnings report date is Aug 07, 2025 which is in 48 days.
How were OmniAb’s earnings last quarter?
OmniAb released its earnings results on May 08, 2025. The company reported -$0.17 earnings per share for the quarter, missing the consensus estimate of -$0.164 by -$0.006.
Is OmniAb overvalued?
According to Wall Street analysts OmniAb’s price is currently Undervalued.
Does OmniAb pay dividends?
OmniAb does not currently pay dividends.
What is OmniAb’s EPS estimate?
OmniAb’s EPS estimate is -0.15.
How many shares outstanding does OmniAb have?
OmniAb has 122,335,335 shares outstanding.
What happened to OmniAb’s price movement after its last earnings report?
OmniAb reported an EPS of -$0.17 in its last earnings report, missing expectations of -$0.164. Following the earnings report the stock price went down -8.28%.
Which hedge fund is a major shareholder of OmniAb?
Currently, no hedge funds are holding shares in OABI
OmniAb Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$7.67 (351.18% Upside)
$7.67 (351.18% Upside)
Hedge Fund Trend
Decreased
By 910.6K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $480.3K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 14.1%
Last 30 Days ▲ 10.3%
Last 30 Days ▲ 10.3%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-60.62%
12-Months-Change
Fundamentals
Return on Equity
-21.32%
Trailing 12-Months
Asset Growth
-13.15%
Trailing 12-Months
Company Description
OmniAb
OmniAb (OABI) is a biotechnology company specializing in the development and commercialization of innovative therapeutic antibody discovery technologies. Operating within the pharmaceutical and biotechnology sectors, OmniAb provides drug discovery platforms that accelerate the development of biologic drugs. Their core products and services include proprietary antibody discovery platforms that leverage advanced technologies to identify and optimize therapeutic antibodies for pharmaceutical companies and academic institutions.
OABI Company Deck
OABI Earnings Call
Q1 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects a positive outlook for OmniAb with strong growth in deals and programs, a successful launch of a new product line, and increased revenue. However, challenges such as net losses and lower royalty revenues persist. Overall, the positives in terms of strategic growth and financial performance outweigh the negatives.Read More>OABI Stock 12 Month Forecast
Average Price Target
$7.67
▲(351.18%Upside)